Part of Diabetes & EndocrineHuman Insulins & Analogs
Recombinant human insulins, biphasic suspensions, and long-acting basal insulin analogs. All formulations listed are procured under PMBI with verified WHO-GMP standard compliance.
Formulation & Pricing Breakdown7 pricedView details
Human Insulins & Analogs Formulations (10)
Find Nearby KendraSoluble Insulin Injection 40 IU per ml (R-DNA Origin)
Recombinant Human Insulin therapy on the WHO Model List of Essential Medicines. Restores glycemic control, facilitates glucose uptake, and suppresses hepatic glucose production in diabetes mellitus.
Biphasic Isophane Insulin Injection 40 IU/ml (30/70)
Recombinant Human Insulin formulation (Regular human insulin, Isophane NPH intermediate-acting insulin, or Biphasic premixed human/analogue insulin) on the WHO Model List of Essential Medicines. It replaces deficient endogenous insulin, binding to membrane insulin receptor tyrosine kinase to promote cellular glucose uptake into skeletal muscle and adipose tissue, stimulate glycogen and protein synthesis, and inhibit lipolysis and hepatic gluconeogenesis. Indicated for type 1 diabetes mellitus, type 2 diabetes mellitus uncontrolled on oral therapies, gestational diabetes, and diabetic ketoacidosis.
Biphasic Isophane Insulin Injection (50:50) 40 IU per ml
Recombinant Human Insulin formulation (Regular human insulin, Isophane NPH intermediate-acting insulin, or Biphasic premixed human/analogue insulin) on the WHO Model List of Essential Medicines. It replaces deficient endogenous insulin, binding to membrane insulin receptor tyrosine kinase to promote cellular glucose uptake into skeletal muscle and adipose tissue, stimulate glycogen and protein synthesis, and inhibit lipolysis and hepatic gluconeogenesis. Indicated for type 1 diabetes mellitus, type 2 diabetes mellitus uncontrolled on oral therapies, gestational diabetes, and diabetic ketoacidosis.
Insulin Glargine Injection 100 IU per ml
Insulin Glargine (100 IU/mL) is a recombinant DNA-origin human insulin analogue with an ultra-long, peakless 24-hour pharmacokinetic profile on the WHO Model List of Essential Medicines. It contains two extra arginine residues at the B-chain C-terminus, shifting its isoelectric point to pH 6.7; upon subcutaneous injection into physiological neutral pH (7.4), it precipitates into a stable microcrystalline depot that releases insulin monomer slowly and constantly over 24 hours, simulating basal physiological insulin secretion. Indicated for once-daily basal glycemic control in type 1 and type 2 diabetes mellitus.
Biphasic Isophane Insulin Injection 100 IU/ml (30/70)
Recombinant Human Insulin formulation (Regular human insulin, Isophane NPH intermediate-acting insulin, or Biphasic premixed human/analogue insulin) on the WHO Model List of Essential Medicines. It replaces deficient endogenous insulin, binding to membrane insulin receptor tyrosine kinase to promote cellular glucose uptake into skeletal muscle and adipose tissue, stimulate glycogen and protein synthesis, and inhibit lipolysis and hepatic gluconeogenesis. Indicated for type 1 diabetes mellitus, type 2 diabetes mellitus uncontrolled on oral therapies, gestational diabetes, and diabetic ketoacidosis.
Soluble Insulin Injection 100 IU per ml (R-DNA Origin)
Recombinant Human Insulin therapy on the WHO Model List of Essential Medicines. Restores glycemic control, facilitates glucose uptake, and suppresses hepatic glucose production in diabetes mellitus.
Insulin Pen
Recombinant Human Insulin therapy on the WHO Model List of Essential Medicines. Restores glycemic control, facilitates glucose uptake, and suppresses hepatic glucose production in diabetes mellitus.
Glargine 100 IU Pre-filled Disposable Pen
Insulin Glargine (100 IU/mL) is a recombinant DNA-origin human insulin analogue with an ultra-long, peakless 24-hour pharmacokinetic profile on the WHO Model List of Essential Medicines. It contains two extra arginine residues at the B-chain C-terminus, shifting its isoelectric point to pH 6.7; upon subcutaneous injection into physiological neutral pH (7.4), it precipitates into a stable microcrystalline depot that releases insulin monomer slowly and constantly over 24 hours, simulating basal physiological insulin secretion. Indicated for once-daily basal glycemic control in type 1 and type 2 diabetes mellitus.
Biphasic Insulin Lispro Injection 100IU per ml (25:75)
Recombinant Human Insulin formulation (Regular human insulin, Isophane NPH intermediate-acting insulin, or Biphasic premixed human/analogue insulin) on the WHO Model List of Essential Medicines. It replaces deficient endogenous insulin, binding to membrane insulin receptor tyrosine kinase to promote cellular glucose uptake into skeletal muscle and adipose tissue, stimulate glycogen and protein synthesis, and inhibit lipolysis and hepatic gluconeogenesis. Indicated for type 1 diabetes mellitus, type 2 diabetes mellitus uncontrolled on oral therapies, gestational diabetes, and diabetic ketoacidosis.
Insulin Aspart Injection 100IU per ml
Recombinant Human Insulin formulation (Regular human insulin, Isophane NPH intermediate-acting insulin, or Biphasic premixed human/analogue insulin) on the WHO Model List of Essential Medicines. It replaces deficient endogenous insulin, binding to membrane insulin receptor tyrosine kinase to promote cellular glucose uptake into skeletal muscle and adipose tissue, stimulate glycogen and protein synthesis, and inhibit lipolysis and hepatic gluconeogenesis. Indicated for type 1 diabetes mellitus, type 2 diabetes mellitus uncontrolled on oral therapies, gestational diabetes, and diabetic ketoacidosis.
Statutory Medical Guidance
All products listed are official PMBI-procured generic drugs and surgical consumables. Schedule H formulations require a valid doctor's prescription for dispensing at Jan Aushadhi Kendras. Always consult a certified healthcare professional before starting or altering any pharmaceutical therapy.